SELENITETRIGLYCERIDES AND THEIR PROMISE IN CANCER TREATMENT
DOI:
https://doi.org/10.56782/pps.105Keywords:
seleninotriglicerydy, selen, potencjał oksydoredukcyjny, antyoksydant, prooksydantAbstract
Selol is a mixture of selenitetriglycerides, which are unique selenium compounds at the +4 oxidation state. In vitro and in vivo studies have shed light on mechanisms essential for the understanding of the biomedical actions of Selol in health and disease. Following administration, Selol has an initial strong pro-oxidative and antineoplastic effect, while in the second phase it exhibits antioxidant and repair properties. Selol is a promising pharmacological agent with antioxidant, anti-inflammatory, neuroprotective and anti-mutagenic properties. Preclinical studies of Selol are currently nearing completion. Non-commercial clinical pilot studies are in progress, and are based on the biological activity profile of Selol. This review summarizes the current knowledge of the biochemical and molecular properties of Selol and outlines future directions in this area of research.
Downloads
References
Fairweather-Tait S. J., Bao Y., Broadley M. R., Collings R., Ford D., Hesketh J. E., Hurst R. Selenium in human health and disease. Antioxid Redox Signal, 2011, 14(7), 1337-1383. DOI: https://doi.org/10.1089/ars.2010.3275
Rayman M. P. Selenium and human health. Lancet, 2012, 379(9822), 1256-1268. DOI: https://doi.org/10.1016/S0140-6736(11)61452-9
Brown K. M., Arthur J. R. Selenium, selenoproteins and human health: a review. Public Health Nutr, 2001, 4(2b), 593-599. DOI: https://doi.org/10.1079/PHN2001143
Madison T.C. Sanitary report – Fort Randall. In Statistical Report on the Sickness and Mortality in the Army of the United States (Coolidge, R.H., ed.). 36th Congress Senate Exchange Document, 1860, 37-41.
Schwarz K., Foltz C. M. Factor 3 activity of selenium compounds. J. Biol. Chem., 1958, 233, 245–251. DOI: https://doi.org/10.1016/S0021-9258(19)68065-8
Combs G. F., Gray W. P. Food system-based approaches to improving micronutrient nutrition: the case for selenium. Biofactors, 2000, 12(1-4), 39-43. DOI: https://doi.org/10.1002/biof.5520120107
Lu J., Holmgren A. Selenoproteins. J Biol Chem, 2009, 284(2), 723-727. DOI: https://doi.org/10.1074/jbc.R800045200
Clark L. C., Dalkin B., Krongrad A., Combs G. F., Jr., Turnbull B. W., Slate E. H., Witherington R., Herlong J. H., Janosko E., Carpenter D., Borosso C., Falk S., Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol, 1998, 81(5), 730-734. DOI: https://doi.org/10.1046/j.1464-410x.1998.00630.x
Blankenberg S., Rupprecht H. J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K. J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med, 2003, 349(17), 1605-1613. DOI: https://doi.org/10.1056/NEJMoa030535
Rederstorff M., Krol A., Lescure A. Understanding the importance of selenium and selenoproteins in muscle function. Cell Mol Life Sci, 2006, 63(1), 52-59. DOI: https://doi.org/10.1007/s00018-005-5313-y
Hatfield D. L., Berry M. J., Gladyshev V. N. Selenium: Its Molecular Biology and Role in Human Health. Springer Science+Business Media, 2012. DOI: https://doi.org/10.1007/978-1-4614-1025-6
Baum M. K., Campa A. Role of selenium in HIV/AIDS. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium – its molecular biology and role in human health. New York: Springer, 2006, 299-310. DOI: https://doi.org/10.1007/0-387-33827-6_26
Broome C. S., McArdle F., Kyle J. A., Andrews F., Lowe N. M., Hart C. A., Arthur J. R., Jackson M. J. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr, 2004, 80(1), 154-162. DOI: https://doi.org/10.1093/ajcn/80.1.154
Rayman M. P., Infante H. G., Sargent M. Food-chain selenium and human health: spotlight on speciation. Br J Nutr, 2008, 100(2), 238-253. DOI: https://doi.org/10.1017/S0007114508922522
Fitak B. A., Grabowski M., Suchocki P. Preparat przeciwnowotworowy i sposób jego wytwarzania. Pol Patent, 1999, 1765301994.
Suchocki P., Jakoniuk D., Fitak B.A. Specific spectrophotometric method with trifluoroacetic acid for the determination of selenium(IV) in selenitetriglycerides. J Pharm Biomed Anal, 2003, 32, 1029-1036. DOI: https://doi.org/10.1016/S0731-7085(03)00205-X
Jastrzebski Z., Czyzewska-Szafran H., Remiszewska M., Fijalek Z., Fitak B. A., Suchocki P. Pharmacokinetics of selol, a new agent containing selenium, in rats. Drugs Exp Clin Res, 1997, 23(1), 7-11.
Jastrzebski Z., Czyzewska-Szafran H., Fijatek Z., Suchocki P., Fitak B. A. Toxicity studies of a new selenium compound, Selol, in rats. Drugs Exp Clin Res, 1995, 21(6), 217-220.
Rahden-Staron I., Suchocki P., Czeczot H. Evaluation of mutagenic activity of the organo-selenium compound Selol by use of the Salmonella typhimurium mutagenicity assay. Mutat Res, 2010, 699(1-2), 44-46. DOI: https://doi.org/10.1016/j.mrgentox.2010.04.018
Schafer F. Q., Buettner G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 2001, 30(11), 1191-1212. DOI: https://doi.org/10.1016/S0891-5849(01)00480-4
Hutter D. E., Till B. G., Greene J. J. Redox state changes in density-dependent regulation of proliferation. Exp Cell Res, 1997, 232(2), 435-438. DOI: https://doi.org/10.1006/excr.1997.3527
Stipanuk M. H., Ueki I., Dominy J. E., Jr., Simmons C. R., Hirschberger L. L. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids, 2009, 37(1), 55-63. DOI: https://doi.org/10.1007/s00726-008-0202-y
Brait M., Ling S., Nagpal J. K., Chang X., Park H. L., Lee J., Okamura J., Yamashita K., Sidransky D., Kim M. S. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One, 2012, 7(9), e44951. DOI: https://doi.org/10.1371/journal.pone.0044951
Sies H. Strategies of antioxidant defense Eur. J. Biochem. , 1993, 215, 213-219. DOI: https://doi.org/10.1111/j.1432-1033.1993.tb18025.x
Carocho M., Ferreira I. C. A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol, 2013, 51, 15-25. DOI: https://doi.org/10.1016/j.fct.2012.09.021
Lushchak V. I. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids, 2012, 2012, 736837. DOI: https://doi.org/10.1155/2012/736837
Stańczyk M., Jaworska M., Wilk M., Suchocki P., Anuszewska E. The effect of selenium on redox state and thiols changes in lung tissue after Selol, a new organoselenium (IV) compound, administration. Central European Journal of Immunology, 2010, 35(3), 115-122.
Suchocki P., Misiewicz I., Skupinska K., Waclawek K., Fijalek Z., Kasprzycka-Guttman T. The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncol Rep, 2007, 18(4), 893-899. DOI: https://doi.org/10.3892/or.18.4.893
Suchocki P., Misiewicz-Krzeminska I., Skupinska K., Niedzwiecka K., Lubelska K., Fijalek Z., Kasprzycka-Guttman T. Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol Rep, 2010, 62(2), 352-361. DOI: https://doi.org/10.1016/S1734-1140(10)70275-9
Curtis D., Klaassen John B., Watkins III, redakcja wydania I polskiego: Barbara Zielińska-Psuja, Andrzej Sapota. Podstawy toksykologii. Casarett & Doull 2014 ISBN: 978-83-7846-058-9, 149-165.
Dudkiewicz-Wilczyńska J., Książek I., Nowak K., Suchocki P., Flis S., Kiljan M., Anuszewska M. Study of the effect of Selol and sodium selenite on HeLa cells in vitro. Chemik, 2011, 65(2), 105-114.
Ksiazek I., Sitarz K., Anuszewska E., Dudkiewicz-Wilczyńska J., Roslon M., Koronkiewicz M., Suchocki P. TOXICITY STUDIES OF SELOL – AN ORGANIC SELENIUM (IV) COMPOUND- IN VITRO RESEARCH International Journal of Pharmacy and Pharmaceutical Sciences 2014, 6(5), 264-269.
Ślusarczyk J., Dudek M., Wierzbicka M., Suchocki P., Kuraś M. Antimitotic effect of Selol and sodium selenate (IV) on Allium test cells. Caryologia, 2014, 67(3), 250-259. DOI: https://doi.org/10.1080/0144235X.2014.974353
Wojciechowska U., Didkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce. Analiza przeżyć pacjentów zdiagnozowanych w latach 2003–2005. Nowotwory. Journal of Oncology, 2013, 63(4), 279-285. DOI: https://doi.org/10.5603/NJO.2013.0014
El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res, 2001, 475(1-2), 123-139. DOI: https://doi.org/10.1016/S0027-5107(01)00075-6
Ksiazek I., Sitarz K., Roslon M., Anuszewska E., Suchocki P., Wilczynska J. D. The influence of Selol on the expression of oxidative stress genes in normal and malignant prostate cells. Cancer Genomics Proteomics, 2013, 10(5), 225-232.
Flis A., Suchocki P., Królikowska M., Suchocka Z., Remiszewska M., Śliwka L., Książek I., Sitarz K., Sochacka M., Hoser G., Anuszewska E., Wroczyński P., Jastrzębski Z. Selenitetriglycerides—Redox-active agents. Pharmacological Reports, 2015, 67(1), 1-8. DOI: https://doi.org/10.1016/j.pharep.2014.07.017
Nguyen T., Sherratt P. J., Nioi P., Yang C. S., Pickett C. B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem, 2005, 280(37), 32485-32492. DOI: https://doi.org/10.1074/jbc.M503074200
Driscoll D. M.,Copeland P. R. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr, 2003, 23, 17-40. DOI: https://doi.org/10.1146/annurev.nutr.23.011702.073318
Hatfield D. L., Gladyshev V. N. How selenium has altered our understanding of the genetic code. Mol Cell Biol, 2002, 22(11), 3565-3576. DOI: https://doi.org/10.1128/MCB.22.11.3565-3576.2002
Lee B. J., Worland P. J., Davis J. N., Stadtman T. C., Hatfield D. L. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem, 1989, 264(17), 9724-9727. DOI: https://doi.org/10.1016/S0021-9258(18)81714-8
Miniard A. C., Middleton L. M., Budiman M. E., Gerber C. A., Driscoll D. M. Nucleolin binds to a subset of selenoprotein mRNAs and regulates their expression. Nucleic Acids Res, 2010, 38(14), 4807-4820. DOI: https://doi.org/10.1093/nar/gkq247
Sochacka M., Giebultowicz J., Remiszewska M., Suchocki P., Wroczynski P. Effects of Selol 5% supplementation on the activity or concentration of antioxidants and malondialdehyde level in the blood of healthy mice. Pharmacol Rep, 2014, 66(2), 301-310. DOI: https://doi.org/10.1016/j.pharep.2013.10.004
Zagrodzki P., Bik D., Fitak B.A., Suchocki P., Niemczuk K. Selenoenzymes in animal tissues after supplementation with SELOL. Bulletin of the Veterinary Institute in Puławy, 2000, 44(2).
Barnham K. J., Masters C. L., Bush A. I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov, 2004, 3(3), 205-214. DOI: https://doi.org/10.1038/nrd1330
Martin H. L.,Teismann P. Glutathione--a review on its role and significance in Parkinson's disease. Faseb j, 2009, 23(10), 3263-3272. DOI: https://doi.org/10.1096/fj.08-125443
Wang A. Z., Langer R., Farokhzad O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med, 2012, 63, 185-198. DOI: https://doi.org/10.1146/annurev-med-040210-162544
Poste G., Kirsh R. Site-Specific (Targeted) Drug Delivery in Cancer Therapy. Nat Biotech, 1983, 1(10), 869-878. DOI: https://doi.org/10.1038/nbt1283-869
Falqueiro A. M., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. Journal of Applied Physics, 2011, 109(7), 07B306. DOI: https://doi.org/10.1063/1.3556950
Falqueiro A. M., Siqueira-Moura M. P., Jardim D. R., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. In vitro cytotoxicity of Selol-loaded magnetic nanocapsules against neoplastic cell lines under AC magnetic field activation. Journal of Applied Physics, 2012, 111(7), 07B335. DOI: https://doi.org/10.1063/1.3680541
Estevanato L. L., Da Silva J. R., Falqueiro A. M., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C., Morais P. C., Lacava Z. G. Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy. Int J Nanomedicine, 2012, 7, 5287-5299. DOI: https://doi.org/10.2147/IJN.S35279
de Souza L. R., Muehlmann L. A., Dos Santos M. S., Ganassin R., Simon-Vazquez R., Joanitti G. A., Mosiniewicz-Szablewska E., Suchocki P., Morais P. C., Gonzalez-Fernandez A., Azevedo R. B., Bao S. N. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells. J Nanobiotechnology, 2014, 12, 32. DOI: https://doi.org/10.1186/s12951-014-0032-x
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
